Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.

Affiliation

Department of Medical Oncology, Gustave Roussy, Villejuif, France; Paris-Sud University, Orsay, France. Electronic address: [Email]

Abstract

Leptomeningeal metastases (LMs) are associated with dismal prognosis in NSCLC. Optimal management remains unknown in patients with EGFR-mutated NSCLC after initial tyrosine kinase inhibitor (TKI) failure.

Keywords

EGFR,Leptomeningeal metastases,NSCLC,Tyrosine kinase inhibitor,